Mustgrow Biologics Corp Stock Price, News & Analysis

MustGrow (OTCQB: MGROF) reported large-scale U.S. potato field results showing material yield, size and quality gains from its organic TerraSanteTM biofertility product.

Customer data in Washington showed an approximate 2 ton/acre yield increase and larger tuber size with fewer culls, which the farmer estimated as about a US$5,000 increase in value per acre at a product cost of US$180/acre. Small-plot trials also showed yield lifts vs untreated: +27.6% at 15 lbs/ac, +25.8% at 20 lbs/ac, and +39.2% at 50 lbs/ac. TerraSante is OMRI listed and registered for sale in CA, FL, AZ, ID, OR, WA. The company highlights soil-microbiome and nutrient-use benefits when used with grower programs.

MustGrow (OTCQB: MGROF) reported Q3-2025 operating and financial results for the three months ended September 30, 2025, announcing its first recorded quarterly sales since the prior-year period.

• Sales revenue: $0.8 million in Q3-2025 vs. no revenue in Q3-2024
• Gross profit: $180,555; gross margin 22.9% (up from 20.9% in Q2-2025)
• Cash and equivalents: $3.3 million as of September 30, 2025
• Inventory: $1.9 million as of September 30, 2025

The company noted Q3 is a seasonal shoulder period for Canadian agriculture and expects stronger retail demand in Q4-2025 and Q1-2026 as farmers buy crop inputs. Management cited margin improvement driven by higher-margin product sales through NexusBioAg and continues to allocate capital toward NexusBioAg and U.S. TerraSante biofertility sales.

MustGrow Biologics (OTCQB: MGROF) announced the grant of 1,660,315 deferred share units (DSUs) and restricted share units (RSUs) to directors, officers, and consultants, effective September 25, 2025. The grants were made under the company's Omnibus Equity Incentive Plan.

The DSUs will vest upon the holder's departure from their role at the company or its affiliates. Upon settlement, DSU holders will receive either one common share or an equivalent cash payment at the company's discretion.

MustGrow Biologics (OTCQB: MGROF) has secured a $2.0 million line of credit (LOC) from CIBC, guaranteed by Export Development Canada. The LOC carries an interest rate of prime rate plus 1.00% (current prime rate: 4.95%).

The funding will be used to produce TerraSante™, the company's organic mustard-derived biofertility product, to meet growing U.S. commercial farming demand. Additionally, the LOC will support working capital requirements for NexusBioAg, MustGrow's Canadian sales and distribution division.

MustGrow Biologics (OTCQB: MGROF) has completed several financial transactions to strengthen its capital structure. The company closed a non-brokered LIFE offering of approximately $2.1 million, issuing 3,059,731 units at $0.70 per unit. Each unit includes one common share and one warrant exercisable at $0.90 for 60 months.

Additionally, MustGrow repriced its January 2025 warrants from $1.90 to $0.90 per share and implemented a shares-for-debt settlement of $2.385 million in convertible debentures through the issuance of approximately 3.4 million shares at $0.70 per share. The proceeds will fund inventory production for TerraSante™ biofertility product and NexusBioAg distribution platform.

MustGrow Biologics (OTCQB: MGROF), a biological and regenerative agriculture solutions provider, reported strong Q2-2025 financial results. The company achieved revenue of $2.8 million, including $312,832 from TerraSante™ biofertility product sales in the U.S., compared to no revenue in Q2-2024.

The company improved its gross profit margin to 20.9% in Q2-2025, up from 14.3% in Q1-2025. TerraSante™ sales in Q2 tripled the entire 2024 sales volume, with inventory selling out due to growing demand. The company maintained a stable financial position with $1.8 million in cash and equivalents and $1.8 million in inventory as of June 30, 2025. The quarter resulted in a net loss of $1.1 million, or $0.02 per basic share.

MustGrow Biologics (OTCQB:MGROF) held its 2025 annual shareholder meeting on June 26, 2025, where all proposed directors were successfully elected with strong shareholder support. Each director received over 95% approval, with most garnering more than 99% of votes.

Shareholders also approved the reappointment of Ernst & Young LLP as auditors and reapproved the company's omnibus equity incentive plan, which remains subject to final TSX Venture Exchange approval.

MustGrow Biologics (MGROF) has signed a distribution agreement with Phospholutions to sell RhizoSorb®, a phosphorous efficiency product, through its Canadian division NexusBioAg. RhizoSorb® is designed to replace conventional phosphate fertilizers by enhancing nutrient use efficiency, allowing farmers to reduce phosphorus application by up to 50% while maintaining or improving crop yields. The product offers potential savings of up to US$20 per acre and significant environmental benefits, including 45.2% reduction in CO2e emissions, 78% reduction in phosphorus runoff, and 84% reduction in leaching compared to conventional MAP fertilizer. With Canada's 94.5 million acres of phosphate-dependent crop production, this partnership aims to deliver more cost-effective and sustainable fertilizer solutions to Canadian retailers and growers.

MustGrow Biologics reported strong Q1-2025 financial results, marking its first full quarter of revenue following the NexusBioAg acquisition. The company achieved $3.8 million in sales revenue compared to zero in Q1-2024, with a gross profit margin of 14.3% ($541,221). Financial position shows $2.0 million in cash and $2.4 million in inventory. The quarter saw a net loss of $1.6 million ($0.03 per share). MustGrow expanded its product portfolio through its NexusBioAg platform, securing a five-year exclusive distribution agreement with Adjuvants Plus Inc. and adding three new biological solutions: EZ-Gro Max, EZ-Gro Cyto, and Rootella® mycorrhizal inoculants. The company focuses on growing both its Canadian distribution business and TerraSante™ biofertility sales in the U.S.